Galapagos Q4 Earnings Call Highlights

Galapagos (NASDAQ:GLPG) executives utilized the company’s year-end 2025 fiscal results telephone to outline a strategical reset centered connected concern development, pursuing a determination to upwind down its compartment therapy activities. Management emphasized that the institution ended 2025 with astir €3 cardinal successful cash, which it views arsenic a cardinal root of flexibility arsenic it searches for “transformative” woody opportunities, chiefly successful inflammation and immunology (I&I) and oncology.

Chief Executive Officer Henry Gosebruch said 2025 was “transformative,” focused connected “turning the leafage from compartment therapy,” implementing a caller strategical direction, and gathering a instauration for semipermanent worth creation. He said the institution has assembled a caller enactment squad with extended transaction acquisition and has besides refreshed its committee with 5 caller directors with superior allocation and operating backgrounds.

→ Gold and Silver Pulled Back—Here’s Why the Bull Case Is Intact

Gosebruch said Galapagos is “aggressively evaluating opportunities” crossed its absorption areas portion remaining “disciplined and selective,” with a penchant for “clinically de-risked opportunities.” He besides described the company’s collaboration with Gilead arsenic a strategical advantage, saying the 2 companies person “active and constructive dialogue” arsenic Galapagos evaluates imaginable transactions.

Gosebruch provided an update connected Galapagos’s bequest R&D asset, the TYK2 inhibitor GLPG3667. He noted that the institution announced top-line Phase 2 results successful December for studies successful dermatomyositis and systemic lupus erythematosus (SLE). According to management, GLPG3667 met the superior endpoint successful dermatomyositis, showing a statistically important objective payment and improvements connected secondary measures versus placebo.